SEQHEPB: A sequence analysis program and relational database system for chronic hepatitis B

Yuen, Lilly; Ayres, Anna; Colledge, Danielle; Edgely, Andrew; Maskill, William J.; Locarnini, Stephen; Bartholomeusz, Angeline

doi:10.1016/j.antiviral.2006.11.014

Cited by 65 publications

(45 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This method has great applicability to the management of chronic hepatitis B. A database that can be used to process HBV DNA sequence information to identify genotype and detect mutations that inhibit HBeAg expression and to predict resistance has been reported (SEQHEPB) (161). Access is provided on a subscription basis.…”

Section: Future Trends In Molecular Diagnostic Testing For Chronic Hementioning

confidence: 99%

Molecular Testing in the Diagnosis and Management of Chronic Hepatitis B

Valsamakis

2007

Clin Microbiol Rev

135

View full text Add to dashboard Cite

SUMMARY Hepatitis B virus (HBV) is an enveloped virus with a small (3.2-kb) partially double-stranded DNA genome that causes acute and chronic infections. The impact of these infections on public health worldwide is enormous, with an estimated prevalence of 2 billion acute infections and 360 million chronic infections globally. This review focuses on chronic hepatitis B and the molecular assays used in its diagnosis and management. Background information, including that about features of the hepatitis B virion, viral replication, and epidemiology of infection, that is important for understanding chronic hepatitis B and molecular diagnostic tests for HBV is provided. To facilitate an understanding of the utility of molecular testing for chronic hepatitis B, the four stages of chronic hepatitis B infection that are currently recognized, as well as an additional entity, occult hepatitis B, that can be diagnosed only by sensitive nucleic acid amplification methods, are reviewed in detail, including available therapeutic agents. The molecular diagnostic content focuses on tests for HBV DNA quantification, genotyping, and mutation detection (including precore/core promoter and antiviral resistance mutations). The discussion of these tests encompasses their current utility and performance characteristics, drawing from current clinical guidelines and other studies from the literature. In recognition of the continual evolution of this field, the final section describes emerging molecular markers with future diagnostic potential.

show abstract

Section: Future Trends In Molecular Diagnostic Testing For Chronic Hementioning

confidence: 99%

Molecular Testing in the Diagnosis and Management of Chronic Hepatitis B

Valsamakis

2007

Clin Microbiol Rev

135

View full text Add to dashboard Cite

show abstract

“…The analysis of 1556 HBsAgS-specific DNA sequences extracted from a HBV database (SeqHepB) (34,62) revealed that asparagine at position 116 or 130 is present in Ͻ1% of the naturally occurring sequences. The amino acids threonine at position 116 and glycine at position 130 are conserved in 99.5% and 98% of the analyzed sequences, respectively.…”

Section: Generation and Characterization Of Differentially Glycosylatedmentioning

confidence: 99%

Modification of Asparagine-Linked Glycan Density for the Design of Hepatitis B Virus Virus-Like Particles with Enhanced Immunogenicity

Hyakumura

Walsh

Thaysen‐Andersen

et al. 2015

J Virol

View full text Add to dashboard Cite

The small envelope proteins (HBsAgS) derived from hepatitis B virus (HBV) represent the antigenic components of the HBV vaccine and are platforms for the delivery of foreign antigenic sequences. To investigate structure-immunogenicity relationships for the design of improved immunization vectors, we have generated biochemically modified virus-like particles (VLPs) exhibiting glycoengineered HBsAgS. For the generation of hypoglycosylated VLPs, the wild-type (WT) HBsAgS N146 glycosylation site was converted to N146Q; for constructing hyperglycosylated VLPs, potential glycosylation sites were introduced in the HBsAgS external loop region at positions T116 and G130 in addition to the WT site. The introduced T116N and G130N sites were utilized as glycosylation anchors resulting in the formation of hyperglycosylated VLPs. Mass spectroscopic analyses showed that the hy-

show abstract

“…Registered users can access the program online, and input either genomic (nucleic acid) or amino acid sequences of clinical HBV isolates for analysis. SeqHepB defines all amino acid variations within the input sequences compared to reference sequence(s) of the same genotype as mutations 37 and correlate the results with a database of HBV genotype and phenotype data and clinical histories. Various data mining algorithms and functions are being developed that facilitate rapid and efficient identification of new markers of drug resistance.…”

Section: Hbv Resistance Databases and Virtual Phenotypingmentioning

confidence: 99%